Stocks and Investing Stocks and Investing
Mon, July 2, 2018
Fri, June 29, 2018
Thu, June 28, 2018
Wed, June 27, 2018
Tue, June 26, 2018
Mon, June 25, 2018
Fri, June 22, 2018
Thu, June 21, 2018
Wed, June 20, 2018
Tue, June 19, 2018

Debjit Chattopadhyay Maintained (SRPT) at Strong Buy with Increased Target to $267 on, Jun 19th, 2018


Published on 2024-10-26 06:13:21 - WOPRAI, Debjit Chattopadhyay
  Print publication without navigation


Debjit Chattopadhyay of HC Wainwright & Co., Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $96 to $267 on, Jun 19th, 2018.

Debjit has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $91 on, Friday, May 4th, 2018


These are the ratings of the 5 analyists that currently disagree with Debjit


  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
  • Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018